Bioidentical hormone therapy: what it is and what we prescribe

Bioidentical hormone therapy means hormones that are molecularly identical to the ones your own body makes. That is the whole definition and it is worth pausing on, because the term has been so heavily marketed that its actual meaning has worn off. 17-beta estradiol is the estradiol your ovaries produced. Micronized progesterone is your progesterone. Testosterone is testosterone. The molecule matters because hormone receptors respond to shape and a receptor that has spent decades interpreting one molecule does not necessarily respond to a chemically related stand-in the same way. This is the genuine scientific idea underneath the marketing and it is the reason we prescribe bioidentical hormones as the foundation of our hormone protocols.

What we will do in this article is more than repeat the marketing. We will draw the honest line between FDA-approved bioidentical products and compounded bioidentical preparations, explain when each earns its place, address the safety history that made a generation of women afraid of hormone therapy and show you exactly what we prescribe and how we watch it.

What bioidentical actually means, beyond the marketing

Every hormone on the pharmacy shelf falls somewhere on a spectrum of similarity to endogenous hormones. At one end sit conjugated equine estrogens, a mixture derived from horse urine and synthetic progestins designed to act like progesterone without being it. At the other end sit estradiol, progesterone and testosterone, the exact molecules human physiology produces. The claim of bioidentical therapy is not that identical molecules are magic. It is that identical molecules do identical things, including the receptor-level effects and the metabolite profiles your body already handles and that this predictability is worth having when a prescription is intended to run for years.

There is a second reason the distinction carries clinical weight. Micronized progesterone, the bioidentical form, has a different side effect and possibly a different risk profile from synthetic progestins in the breast and cardiovascular literature and trials such as those reviewed in the Menopause Society's 2022 position statement treat the choice of progestogen as a real clinical decision rather than an interchangeable detail.

FDA-approved versus compounded, the honest line

Here is the distinction most BHRT marketing blurs and we will not. FDA-approved bioidentical products exist, have been through the agency's review and include estradiol patches, tablets and gels, micronized progesterone capsules and testosterone formulations. Where a manufactured product provides the dose and route a patient needs, it is our first choice, full stop. It has a reviewed manufacturing process, standardized dosing and the pharmacovigilance system behind it.

Compounded bioidentical preparations occupy a different role. A compounding pharmacy prepares hormones for an individual prescription, which allows doses, combinations and delivery forms no manufacturer offers, including the BIEST combinations some of our protocols use. The trade is explicit: as finished products these preparations are not FDA-reviewed the way manufactured drugs are, so their standardization depends on the pharmacy. The Menopause Society's position, which we follow, is that FDA-approved products should be first choice where they fit and compounding should be reserved for documented clinical need. That is exactly how we practice.

The safety history, told properly

Most fear of hormone therapy traces to one study and one misreading of it. The Women's Health Initiative published in 2002 reported increased breast cancer and cardiovascular risk in women taking hormone therapy and prescriptions fell by half within two years. What the headlines omitted was the population: the average participant was in her mid-sixties, a decade or more past menopause, taking conjugated equine estrogens with medroxyprogesterone acetate. Neither the chemistry nor the timing describes the therapy a healthy 49-year-old with debilitating symptoms receives today.

The modern position, built on two decades of reanalysis and newer trials, is that for most healthy women within ten years of menopause or under age 60, hormone therapy is the most effective treatment for moderate to severe vasomotor symptoms and the risk profile depends on age, timing, dose and route. Transdermal estradiol carries a different clotting profile from oral estrogen. Micronized progesterone differs from synthetic progestins. None of this makes hormone therapy riskless. It makes it a decision to be made with your history, your exam and your labs, which is precisely what a membership model exists to support.

What we prescribe and how the decision is made

Our hormone protocols begin with the full panel, not with a symptom checklist. The comprehensive Biomarker Audit we run every 90 days carries estradiol, progesterone where relevant, total and free testosterone with SHBG, a full thyroid panel, HbA1c with insulin markers, lipids including ApoB and hs-CRP, because hormones act on the same metabolic and cardiovascular systems those markers measure. Weight, blood sugar, lipids and hormones are one system. Prescribing into one lane while ignoring the others is how med spa protocols produce patients who feel worse on hormones that are technically dosed correctly.

From that panel the protocol prescribes. For women in perimenopause and menopause, that is typically transdermal estradiol with micronized progesterone, dosed to symptoms and verified against labs. For men with a confirmed diagnosis, bioidentical testosterone with hematocrit, PSA and estradiol follow-up. For thyroid findings, levothyroxine or combination protocols as the full panel supports. Where an individualized dose or combination is clinically appropriate, compounded bioidentical preparations are used and their source pharmacy is named. Branded, FDA-approved GLP-1 medication is the only GLP-1 we ever prescribe, under any circumstance and that rule does not bend for anyone.

What it costs, stated plainly

The Cardiometabolic Optimization Membership is a flat $299 a month. The first charge at checkout is $598, one combined amount covering the first two months together: the clinical intake, the first comprehensive Biomarker Audit and the second month of care while your protocol is built. From month three it is $299 a month, month to month and you can cancel anytime after the initial commitment. Four full audits per year sit inside that fee.

Medication is a separate charge, billed by your pharmacy at its own price with zero markup from us. No molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine. We make money when you get healthier, not when your dose gets stronger, which is why the dose conversation in hormone care follows the labs rather than a revenue schedule.

Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network, with additional labs beyond the quarterly cadence billed at pass-through cost.

Who this is for and who it is not

If you are in perimenopause with symptoms nobody connected, our guide to perimenopause weight gain covers the mechanism and the panel behind it. If you are a man with the low testosterone pattern, the real workup article is its companion. Both end at the same place: hormones prescribed against labs, monitored quarterly, inside a system that watches the whole patient.

If you want pellet insertions every three months without labs, a peptide stack from a med spa or hormones renewed forever without a diagnosis, we are the wrong practice and the honesty is deliberate. If you want the opposite, start with the eligibility assessment. Two minutes, no card and a clinician reviews every application because not everyone is accepted.

FAQ

What is bioidentical hormone therapy? Therapy using hormones molecularly identical to your own, most commonly 17-beta estradiol, micronized progesterone and testosterone. Receptors respond to molecular shape and identical molecules produce the receptor activity your physiology already interprets.

Are bioidentical hormones FDA approved? Many are, including estradiol patches and gels and micronized progesterone. Compounded bioidentical preparations are not FDA-reviewed as finished products, though the hormones inside them are the same bioidentical molecules. Both have legitimate roles and the distinction should be stated by anyone selling either.

Is compounded bioidentical hormone therapy safe? It trades standardization for individualization. Guidance from the Menopause Society reserves compounding for documented clinical need and prefers FDA-approved products where they fit, which is how we prescribe.

Is hormone therapy safe for menopause symptoms? For most healthy women within ten years of menopause or under age 60, the modern evidence supports it as the most effective treatment for moderate to severe vasomotor symptoms, with risk depending on age, timing and route. The 2002 alarm described an older population on different chemistry.

What hormones do you prescribe? Estradiol, micronized progesterone and testosterone for women, testosterone for confirmed male hypogonadism and thyroid hormone where the panel supports it. FDA-approved bioidentical products first, compounded bioidentical preparations where individualized dosing is appropriate.

How is therapy monitored? Through the quarterly Biomarker Audit, read against baseline and symptoms, with dose changes following the trend and the way you feel rather than the calendar.

What does it cost? The membership is a flat $299 a month after a $598 first charge covering the first two months together, including four Biomarker Audits per year. Medication is billed separately by your pharmacy at cost with zero markup.

Related Reading

• Perimenopause weight gain: what the hormone panel shows
• Low testosterone symptoms in men: what a real workup checks
• Hormone optimization at GoodLife Health
• Biomarker audits vs standard blood tests

References

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. 2022. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
2. Human Drug Compounding (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/human-drug-compounding